A cell therapy biotech finds a delivery partner; FDA removes clinical hold on Ocugen's Covid candidate
Umoja Biopharma will pair its so-called VivoVec particles with Lupagen’s Side CAR-T delivery system to target certain cancers, the companies said Monday.
As part of the deal, Umoja’s cell therapies could be delivered via an additional route thanks to Lupagen’s extracorporeal in vivo tech. The Dallas gene therapy company’s tech is expected to provide efficiency and “highly controlled viral vector targeting of T cells,” the companies added.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.